Information Journal Paper
APA:
Copy. (2019). Safety, activity, and molecular heterogeneity following neoadjuvant nonpegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an openlabel, single-group, multicenter, phase 2 trial. BMC MEDICINE, 17(1), 0-0. SID. https://sid.ir/paper/704208/en
Vancouver:
Copy. Safety, activity, and molecular heterogeneity following neoadjuvant nonpegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an openlabel, single-group, multicenter, phase 2 trial. BMC MEDICINE[Internet]. 2019;17(1):0-0. Available from: https://sid.ir/paper/704208/en
IEEE:
Copy, “Safety, activity, and molecular heterogeneity following neoadjuvant nonpegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an openlabel, single-group, multicenter, phase 2 trial,” BMC MEDICINE, vol. 17, no. 1, pp. 0–0, 2019, [Online]. Available: https://sid.ir/paper/704208/en